Wolfe Research Assumes argenx SE (ARGX) at Outperform

Wolfe Research analyst Andrew Galler assumes coverage on argenx SE (NASDAQ: ARGX) with a Outperform rating.

The analyst comments "In this deck, we discuss key investor debates such as efgartigimod's position in the FcRn pecking order, the approvability and launch expectations for efgartigimod in gMG, and expectations for ITP and PV."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $309.40 yesterday.

You May Also Be Interested In

• Wells Fargo Starts First Industrial Realty Trust (FR) at Equal Weight
• UBS Starts Fulgent Genetics (FLGT) at Neutral
• Wells Fargo Starts Match Group (MTCH) at Equal Weight